WIZ CORP, Inc. (KOSDAQ:038620)

Ligand Pharmaceuticals Income Statement

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	106,843	104,652	56,066	41,214	33,198	28,207
Revenue	106,843	104,652	56,066	41,214	33,198	28,207
Revenue Growth (YoY)	55.05%	86.66%	36.04%	24.15%	17.70%	-23.26%
Cost of Revenue	85,280	82,990	44,576	32,822	26,585	21,341
Gross Profit	21,563	21,661	11,490	8,392	6,613	6,866
Selling, General & Admin	16,798	16,699	9,581	6,058	4,949	5,536
Research & Development	154	107.2	94	-	-	1.76
Other Operating Expenses	428.39	404.37	400.27	319	317.55	384.21
Operating Expenses	19,130	18,863	10,626	6,698	5,715	6,654
Operating Income	2,433	2,798	864.51	1,694	897.67	212.11
Interest Expense	-772.96	-915.9	-520.79	-0.24	-310.53	-181.83
Interest & Investment Income	881.82	923.45	903.9	545.38	236.52	172.49
Earnings From Equity Investments	-1,267	-1,865	-683.35	3,088	-	-
Currency Exchange Gain (Loss)	0.43	0.35	7.7	-	-5.45	118.01
Other Non Operating Income (Expenses)	968.33	1,035	422.55	508.04	-8,800	-237.29
EBT Excluding Unusual Items	2,244	1,976	994.52	5,835	-7,982	83.49
Gain (Loss) on Sale of Investments	-295.66	-241.21	889.71	-639.68	2,622	2,526
Gain (Loss) on Sale of Assets	-11.1	-11.1	13.84	-142.2	436.84	468.73
Other Unusual Items	-105.41	-105.41	-	-	541.01	27.52
Pretax Income	1,832	1,618	1,898	5,053	-4,382	3,106
Income Tax Expense	646.08	531.98	303.9	905.67	1,051	373.79
Earnings From Continuing Operations	1,186	1,086	1,594	4,148	-5,433	2,732
Earnings From Discontinued Operations	-	-	-	-1,547	-312.82	-
Net Income to Company	1,186	1,086	1,594	2,601	-5,746	2,732
Minority Interest in Earnings	-419.31	-741.14	-162.3	245.38	34.87	68.33
Net Income	766.73	345.11	1,432	2,846	-5,711	2,801
Net Income to Common	766.73	345.11	1,432	2,846	-5,711	2,801
Net Income Growth	-0.36%	-75.90%	-49.69%	-	-	5091.01%
Shares Outstanding (Basic)	64	63	63	63	59	58
Shares Outstanding (Diluted)	64	63	63	63	59	58
Shares Change (YoY)	2.63%	0.56%	-	5.91%	2.09%	-
EPS (Basic)	11.89	5.46	22.78	45.29	-96.24	48.19
EPS (Diluted)	11.89	5.46	22.78	45.29	-96.27	48.19
EPS Growth	-2.92%	-76.03%	-49.69%	-	-	5091.01%
Free Cash Flow	6,129	2,810	1,382	106.89	825.66	1,279
Free Cash Flow Per Share	95.02	44.47	21.99	1.70	13.91	22.01
Gross Margin	20.18%	20.70%	20.49%	20.36%	19.92%	24.34%
Operating Margin	2.28%	2.67%	1.54%	4.11%	2.70%	0.75%
Profit Margin	0.72%	0.33%	2.55%	6.91%	-17.20%	9.93%
Free Cash Flow Margin	5.74%	2.69%	2.46%	0.26%	2.49%	4.54%
EBITDA	6,768	7,070	2,233	2,710	2,171	1,065
EBITDA Margin	6.33%	6.76%	3.98%	6.58%	6.54%	3.77%
D&A For EBITDA	4,335	4,272	1,369	1,016	1,273	852.75
EBIT	2,433	2,798	864.51	1,694	897.67	212.11
EBIT Margin	2.28%	2.67%	1.54%	4.11%	2.70%	0.75%
Effective Tax Rate	35.26%	32.87%	16.01%	17.92%	-	12.03%
Advertising Expenses	-	1,814	474.37	2.32	3.72	8.81

Updated Mar 18, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.